Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer

被引：6
|
作者：
Ros, Javier [1 ]
Elez, Elena [1 ]
机构：
[1] Vall DHebron Hosp, Med Oncol, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 172卷
关键词：
D O I：
10.1016/j.ejca.2022.06.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：326 / 328
页数：3
相关论文
共 50 条
  • [31] Landscape of BRAF-V600E mutant colorectal cancer management in Latin America
    Coutinho, A.
    Cavalcante Gifoni, M.
    Jansen, A.
    Rico-Restrepo, M.
    O'Connor, J.
    Sanku, G.
    Mendez, G.
    Samame Perez-Vargas, J.
    Blanco, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S46 - S46
  • [32] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
    Shahjehan, F.
    Kamatham, S.
    Chandrasekharan, C.
    Kasi, P. M.
    DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
  • [33] Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
    Calegari, Maria Alessandra
    Di Stefano, Brunella
    Basso, Michele
    Carbone, Carmine
    Camarda, Floriana
    Ribelli, Marta
    Anghelone, Annunziato
    Vivolo, Raffaella
    Bensi, Maria
    Martini, Maurizio
    Pozzo, Carmelo
    Vellone, Maria
    Ardito, Francesco
    Salvatore, Lisa
    Giuliante, Felice
    Tortora, Giampaolo
    CLINICAL COLORECTAL CANCER, 2021, 20 (04) : 364 - 367
  • [34] Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC
    von der Heyde, E.
    Buerkle, D.
    Forstbauer, H.
    Huebner, G.
    Schmidt, B.
    Schroeder, J.
    Distelrath, A.
    Wierecky, J.
    Stuebs, P.
    Kisro, J.
    Welslau, M.
    Mueller-Huesmann, H.
    Goehler, T.
    Krammer-Steiner, B.
    Schwaner, I.
    Hering-Schubert, C.
    Gerger, A.
    Greil, R.
    Jacobasch, L.
    Reichenbach, F.
    Stintzing, S.
    Prager, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S248 - S248
  • [35] Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
    Ros Montana, F. J.
    Navarro, V.
    Comas, R.
    Landolfi, S.
    Ramirez, L.
    Palmer, H. G.
    Garcia Rodriguez, A.
    Saoudi Gonzalez, N.
    Baraibar Argota, I.
    Rodriguez Castells, M.
    Salva Ballabrera, F.
    Tabernero, J.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S447 - S447
  • [36] Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
    Wang, Xicheng
    Deng, Yanhong
    Zhang, Yanqiao
    Liu, Tianshu
    Yuan, Xianglin
    Yang, Jianwei
    Zhang, Tao
    Zang, Ai-min
    Liu, Yu
    Huang, Li
    Ye, Feng
    Zong, Hong
    Ba, Yi
    Klauck, Isabelle
    Vedovato, Jean-Claude
    Groc, Melanie
    Guo, Angela
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3559 - LBA3559
  • [37] Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
    Ros, Javier
    Rodriguez-Castells, Marta
    Saoudi, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Tabernero, Josep
    Elez, Elena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (08) : 797 - 806
  • [38] Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report
    Gallois, Claire
    Taieb, Julien
    Sabouret, Annabelle
    Broudin, Chloe
    Karoui, Mehdi
    Garinet, Simon
    Zaanan, Aziz
    GENES CHROMOSOMES & CANCER, 2022, 61 (02): : 114 - 118
  • [39] Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
    Qiu, M.
    Wei, G.
    Leng, W.
    Cao, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S446 - S446
  • [40] Cetuximab every second week in combination with daily encorafenib in patients with BRAF V600E mutated metastatic colorectal cancer: Interim analysis from NEW BEACON.
    Eriksen, Martina
    Pfeiffer, Per
    Rohrberg, Kristoffer Staal
    Yde, Christina Westmose
    Petersen, Lone Norgard
    Poulsen, Laurids
    Qvortrup, Camilla
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 153 - 153
12345